Related Experiment Video

Updated: Jun 5, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

994

Successful Treatment of Mogamulizumab-Associated Rash With Upadacitinib: Evidence From 2 Cases

Daniel Martín-Torregrosa1,2, Ignacio Torres-Navarro1,2, Miguel Mansilla-Polo1,2

  • 1Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

JAMA Dermatology
|December 11, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

Related Experiment Videos

Last Updated: Jun 5, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

994
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115

Articles linked to this work by shared authors, journal, and citation graph.

Real-World Outcomes and Safety of JAK Inhibitors in Paediatric Alopecia Areata: A Retrospective Multicentre Study.

The Australasian journal of dermatology·2026

Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs.

Dermatology and therapy·2026

Pediatric Melanoma: Emerging Therapies and Ongoing Clinical Trials.

Dermatology and therapy·2026

Clinical Features of Hidradenitis Suppurativa in Down Syndrome Patients: A Multicenter Spanish Study.

Journal of cutaneous medicine and surgery·2026

Secondary Malignancies After Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy·2026

Improving Risk Stratification for SLNB in Elderly Patients With Melanoma: The SENTINOLD Nomogram.

International journal of dermatology·2026

Risk Stratification Models for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant.

JAMA dermatology·2026

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.

JAMA dermatology·2026

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa.

JAMA dermatology·2026

Pyoderma Gangrenosum Phenotype Classification.

JAMA dermatology·2026

Enfortumab Vedotin-Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma.

JAMA dermatology·2026

Early Respiratory Infection Burden and Atopic Dermatitis in Childhood.

JAMA dermatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us